Compare AbbVie Inc (ABBV) vs Danaher Corporation (DHR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Danaher Corporation — how do they compare? AbbVie Inc trades at $253.56 (market cap $449.91B), while Danaher Corporation trades at $190.98 (market cap $137.44B). The key difference: AbbVie Inc is far larger — about 3.3× Danaher Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | DHR | |
|---|---|---|
Market Cap | $449.91B | $137.44B |
Sector | Health | Health |
52-Week High | $261.07 | $242.05 |
52-Week Low | $184.85 | $161.91 |
Enterprise Value | $513.38B | $150.22B |
Dividend Yield | 2.72% | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Danaher (DHR) trades at $193.62, down 2.18% today but remains in a bullish technical trend with strong support near $190. The company demonstrates solid fundamentals with a 58.94% gross margin and consistent earnings beats in recent quarters. Recent news highlights strategic collaborations and a pending acquisition of Masimo, approved by shareholders in May 2026, signaling growth initiatives.
The outlook is positive with a consensus price target of $214.73, implying 11% upside. Key risks include revenue stagnation and a high P/E ratio of 37.52. Analyst sentiment is strongly bullish (69% buy ratings), but investors should monitor execution on acquisitions and bioprocessing demand trends for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
